The MErCuRIC team met at UZA in Antwerp for our Year 3 meeting (05 – 06 Dec 2016). We discussed progress in the Phase I trial from the previous year, and mapped our clinical and translational activities for the coming year. As the dose escalation phase I study draws to a close, we are planning […]
This author has yet to write their bio.Meanwhile lets just say that we are proud mercuric contributed a whooping 50 entries.
Entries by mercuric
The latest newsletter from EUPATI is now available. This issue covers an update on national activities across Europe and metrics on use of the EUPATI website.
MErCuRIC results were presented in a poster at the NCRI Cancer Conference in Liverpool, UK on 08 Nov 2016 (Session B, 08:15-11:00). The conference ‘showcases the latest basic, translational and clinical cancer research. It brings researchers together to share ideas and develop collaborations.’ ‘MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced […]
The latest newsletter from EUPATI is now available. This issue covers an update on national activities in 18 countries and information on the upcoming EUPATI 2016 conference All Aboard to a Better Health Future on 14 Dec 2016.
The MErCuRIC Phase I trial was presented at the ESMO 2016 Congress in Copenhagen (7 – 11 Oct 2016). MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours (Poster: 480P) R. Wilson, M. Middleton, J. Houlden, S. Van Schaeybroeck, C. Rolfo, E. Elez, J. Taieb , […]
Technologies to isolate and analyse liquid biopsy samples are rapidly evolving. MErCuRIC researcher Federica Di Nicolantonio discusses the technique in this video produced with ESMO.
The summer 2016 newsletter for the European Patients’ Academy (EUPATI) is now available. In this issue, you can access the Patient Expert Training Course, now available in English, as well as learn about the growing national EUPATI teams that function as patient involvement groups locally.
Congratulations to Prof. Alberto Bardelli of UNITO on his election as President of the European Association for Cancer Research (EACR)! You can read more here.
While the ever-advancing landscape of precision medicine in oncology undoubtedly brings fresh hope for patients, it also poses many yet unanswered questions as to how we move forward, without the real risk of burn-out of those who treat them – particularly with regards to the up-and- coming generation of young oncologists, the future of our profession and practice. Established […]
In June 2016, the Northern Ireland Cancer Research Consumer Forum and its Bowel Cancer Research Interest Group hosted a public event – ‘Delivering 21st Century Medicine for bowel cancer patients’. A MErCuRIC poster was displayed at the event in Belfast. The event was opened by a member of the Local Assembly and speakers included MErCuRIC researcher […]
- ‘Trialling tailored treatments for colorectal cancer’: A European Commission Research & Innovation Success StoryApril 16, 2018 - 10:46 am
- MErCuRIC study published in Molecular Cancer TherapeuticsMarch 6, 2018 - 10:14 am
- MErCuRIC team from RECETOX, Masarykova Univerzita publish study resultsMarch 5, 2018 - 9:11 am
MErCuRIC is funded by the European Community’s Framework Programme Seven (FP7) under contract #602901. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.